The Manufacturers Life Insurance Company Has $1.81 Million Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

The Manufacturers Life Insurance Company lowered its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 1.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,689 shares of the biopharmaceutical company’s stock after selling 368 shares during the period. The Manufacturers Life Insurance Company’s holdings in Intra-Cellular Therapies were worth $1,811,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of ITCI. China Universal Asset Management Co. Ltd. boosted its position in Intra-Cellular Therapies by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock valued at $1,878,000 after buying an additional 2,157 shares in the last quarter. Barclays PLC boosted its position in Intra-Cellular Therapies by 282.0% in the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock valued at $2,521,000 after buying an additional 25,435 shares in the last quarter. Oak Ridge Investments LLC boosted its position in Intra-Cellular Therapies by 74.1% in the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock valued at $1,656,000 after buying an additional 8,440 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Intra-Cellular Therapies by 3.3% in the third quarter. Principal Financial Group Inc. now owns 597,713 shares of the biopharmaceutical company’s stock valued at $43,735,000 after buying an additional 18,865 shares during the period. Finally, Merit Financial Group LLC acquired a new position in shares of Intra-Cellular Therapies in the fourth quarter valued at approximately $206,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

Shares of ITCI opened at $131.87 on Monday. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.98. The business’s 50 day moving average price is $131.73 and its two-hundred day moving average price is $112.40. The firm has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. Research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ITCI shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research note on Friday, February 21st. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $132.00 target price on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Wednesday, May 7th. They set a “hold” rating on the stock. Canaccord Genuity Group downgraded Intra-Cellular Therapies from a “buy” rating to a “hold” rating and lifted their target price for the stock from $119.00 to $132.00 in a report on Friday, January 31st. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $132.00 target price (up from $107.00) on shares of Intra-Cellular Therapies in a report on Tuesday, January 14th. Eleven analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $109.70.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.